Buscar resultados de ensayos clínicos
Salivary Gland Neoplasms - 20 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors Condición:
Fecha: 2016-09-30 Intervenciones:
|
Recruiting |
Nombre del estudio: Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors Condición:
Fecha: 2016-05-12 Intervenciones:
|
Completed |
Nombre del estudio: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Condición: Malignant Salivary Gland Tumors Fecha: 2011-12-07 Intervenciones:
|
Recruiting |
Nombre del estudio: Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers Condición: Salivary Glands Tumors Fecha: 2016-08-11 Intervenciones: Drug: Abiraterone acetate Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of |
Completed |
Nombre del estudio: Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Condición: Head and Neck Cancer Fecha: 2004-03-08 Intervenciones:
|
Recruiting |
Nombre del estudio: Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery Condición: Head and Neck Cancer Fecha: 2010-10-12 Intervenciones:
|
Recruiting |
Nombre del estudio: A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes Condición:
|
Recruiting |
Nombre del estudio: Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample Condición:
|
Withdrawn |
Nombre del estudio: Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Condición:
Intervenciones: |
Recruiting |
Nombre del estudio: Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Condición: Salivary Gland Cancers Fecha: 2016-05-06 Intervenciones: Drug: Axitinib Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hour |